The Cancer Immunotherapy Guidelines Oversight Committee oversees the development of new disease-specific guidelines and updates for existing guidelines that provide guidance on the appropriate treatment algorithms and recommended administration of FDA-approved cancer immunotherapies as well as mitigating and managing adverse event. The oversight committee maintains standards for the SITC Cancer Immunotherapy Guidelines Expert Panels to ensure the recommendations are unbiased, relevant and facilitate clinical decision-making leading to optimal patient care.
Ashish M. Kamat, MD, MBBS, FACS
The University of Texas MD Anderson Cancer Center
James L. Gulley, MD, PhD, FACP
National Cancer Institute